• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗多发性骨髓瘤抗体与人 GPRC5D 同源二聚体的结合机制。

The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer.

机构信息

iHuman Institute, ShanghaiTech University, Shanghai, China.

School of Life Science and Technology, Shanghai Key Laboratory of High-resolution Electron Microscopy, ShanghaiTech University, Shanghai, China.

出版信息

Nat Commun. 2024 Jun 19;15(1):5255. doi: 10.1038/s41467-024-49625-y.

DOI:10.1038/s41467-024-49625-y
PMID:38898050
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11187071/
Abstract

GPRC5D is an atypical Class C orphan G protein-coupled receptor. Its high expression on the surface of multiple myeloma cells has rendered it an attractive target for therapeutic interventions, including monoclonal antibodies, CAR-T cells, and T-cell engagers. Despite its therapeutic potential, the insufficient understanding regarding of the receptor's structure and antibody recognition mechanism has impeded the progress of effective therapeutic development. Here, we present the structure of GPRC5D in complex with a preclinical-stage single-chain antibody (scFv). Our structural analysis reveals that the GPRC5D presents a close resemblance to the typical Class C GPCRs in the transmembrane region. We identify a distinct head-to-head homodimer arrangement and interface mainly involving TM4, setting it apart from other Class C homo- or hetero-dimers. Furthermore, we elucidate the binding site engaging a sizable extracellular domain on GPRC5D for scFv recognition. These insights not only unveil the distinctive dimer organization of this unconventional Class C GPCR but also hold the potential to advance drug development targeting GPRC5D for the treatment of multiple myeloma.

摘要

GPRC5D 是一种非典型的 C 类孤儿 G 蛋白偶联受体。其在多发性骨髓瘤细胞表面的高表达使其成为治疗干预的一个有吸引力的靶点,包括单克隆抗体、CAR-T 细胞和 T 细胞衔接子。尽管具有治疗潜力,但由于对该受体结构和抗体识别机制的了解不足,阻碍了有效治疗方法的开发进展。在这里,我们展示了 GPRC5D 与一种临床前阶段的单链抗体(scFv)复合物的结构。我们的结构分析表明,GPRC5D 在跨膜区域与典型的 C 类 GPCR 具有非常相似的结构。我们确定了一种独特的头对头同源二聚体排列和主要涉及 TM4 的界面,使其与其他 C 类同型或异型二聚体区分开来。此外,我们阐明了与 GPRC5D 上相当大的细胞外结构域结合的 scFv 识别结合位点。这些见解不仅揭示了这种非典型 C 类 GPCR 的独特二聚体组织,而且有可能推进针对多发性骨髓瘤的 GPRC5D 药物开发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679d/11187071/5757f5333fdd/41467_2024_49625_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679d/11187071/813617193848/41467_2024_49625_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679d/11187071/e40ce1adb128/41467_2024_49625_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679d/11187071/977af27e089f/41467_2024_49625_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679d/11187071/5757f5333fdd/41467_2024_49625_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679d/11187071/813617193848/41467_2024_49625_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679d/11187071/e40ce1adb128/41467_2024_49625_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679d/11187071/977af27e089f/41467_2024_49625_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/679d/11187071/5757f5333fdd/41467_2024_49625_Fig4_HTML.jpg

相似文献

1
The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer.抗多发性骨髓瘤抗体与人 GPRC5D 同源二聚体的结合机制。
Nat Commun. 2024 Jun 19;15(1):5255. doi: 10.1038/s41467-024-49625-y.
2
Structural Basis for the Recognition of GPRC5D by Talquetamab, a Bispecific Antibody for Multiple Myeloma.GPRC5D 识别的结构基础,Talquetamab,一种用于多发性骨髓瘤的双特异性抗体。
J Mol Biol. 2024 Oct 15;436(20):168748. doi: 10.1016/j.jmb.2024.168748. Epub 2024 Aug 22.
3
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.GPRC5D 是一种经理性设计的 CAR T 细胞免疫疗法的多发性骨髓瘤的靶点。
Sci Transl Med. 2019 Mar 27;11(485). doi: 10.1126/scitranslmed.aau7746.
4
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.GPRC5D 作为多发性骨髓瘤治疗的新靶点:一篇叙述性评论。
Blood Cancer J. 2024 Feb 2;14(1):24. doi: 10.1038/s41408-023-00966-9.
5
A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma.一种双特异性 G 蛋白偶联受体家族 5 成员 D x CD3 T 细胞导向抗体,用于治疗多发性骨髓瘤。
Blood. 2020 Apr 9;135(15):1232-1243. doi: 10.1182/blood.2019003342.
6
Anti-GPRC5D/CD3 Bispecific T-Cell-Redirecting Antibody for the Treatment of Multiple Myeloma.用于治疗多发性骨髓瘤的抗 GPRC5D/CD3 双特异性 T 细胞重定向抗体。
Mol Cancer Ther. 2019 Sep;18(9):1555-1564. doi: 10.1158/1535-7163.MCT-18-1216. Epub 2019 Jul 3.
7
Targeting GPRC5D for multiple myeloma therapy.针对多发性骨髓瘤的治疗靶点 GPRC5D。
J Hematol Oncol. 2024 Sep 28;17(1):88. doi: 10.1186/s13045-024-01611-z.
8
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.复发或难治性多发性骨髓瘤患者中的GPRC5D嵌合抗原受体T细胞(OriCAR-017)(北极星研究):一项首次人体、单中心、单臂1期试验。
Lancet Haematol. 2023 Feb;10(2):e107-e116. doi: 10.1016/S2352-3026(22)00372-6.
9
A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models.一种新型的 T 细胞重定向抗 GPRC5D×CD3 双特异性抗体,在多发性骨髓瘤的临床前模型中具有强大的抗肿瘤活性。
Sci Rep. 2024 Mar 1;14(1):5135. doi: 10.1038/s41598-024-55143-0.
10
Targeting GPRC5D in multiple myeloma.靶向多发性骨髓瘤中的 GPRC5D。
Expert Rev Anticancer Ther. 2024 May;24(5):229-238. doi: 10.1080/14737140.2024.2343114. Epub 2024 Apr 16.

引用本文的文献

1
From Multi-Omics to Visualization and Beyond: Bridging Micro and Macro Insights in CAR-T Cell Therapy.从多组学到可视化及其他:在CAR-T细胞疗法中连接微观与宏观见解
Adv Sci (Weinh). 2025 May;12(20):e2501095. doi: 10.1002/advs.202501095. Epub 2025 May 11.
2
Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma.GPRC5D靶向治疗在复发难治性多发性骨髓瘤中的应用。
Cancer Med. 2025 Mar;14(6):e70764. doi: 10.1002/cam4.70764.

本文引用的文献

1
Integrating Immune Therapies for the Treatment of Multiple Myeloma.整合免疫疗法治疗多发性骨髓瘤。
J Natl Compr Canc Netw. 2023 Dec;21(12):1303-1311. doi: 10.6004/jnccn.2023.7100.
2
Talquetamab in multiple myeloma.塔奎单抗治疗多发性骨髓瘤。
Haematologica. 2024 Mar 1;109(3):718-724. doi: 10.3324/haematol.2023.283931.
3
Targeting cancer hallmark vulnerabilities in hematologic malignancies by interfering with Hedgehog/GLI signaling.通过干扰 Hedgehog/GLI 信号靶向血液系统恶性肿瘤的癌症标志脆弱性。
Blood. 2023 Dec 7;142(23):1945-1959. doi: 10.1182/blood.2021014761.
4
Structural insights into ligand recognition and activation of the medium-chain fatty acid-sensing receptor GPR84.结构洞察配体识别和激活中链脂肪酸感应受体 GPR84。
Nat Commun. 2023 Jun 6;14(1):3271. doi: 10.1038/s41467-023-38985-6.
5
The activation mechanism and antibody binding mode for orphan GPR20.孤儿GPR20的激活机制及抗体结合模式。
Cell Discov. 2023 Feb 28;9(1):23. doi: 10.1038/s41421-023-00520-8.
6
GPRC5D as a novel immunotherapeutic target in multiple myeloma.GPRC5D作为多发性骨髓瘤的一种新型免疫治疗靶点。
Nat Rev Clin Oncol. 2023 May;20(5):281-282. doi: 10.1038/s41571-023-00735-4.
7
GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.复发或难治性多发性骨髓瘤患者中的GPRC5D嵌合抗原受体T细胞(OriCAR-017)(北极星研究):一项首次人体、单中心、单臂1期试验。
Lancet Haematol. 2023 Feb;10(2):e107-e116. doi: 10.1016/S2352-3026(22)00372-6.
8
Cryo-EM structures of orphan GPR21 signaling complexes.孤儿 GPR21 信号复合物的冷冻电镜结构。
Nat Commun. 2023 Jan 13;14(1):216. doi: 10.1038/s41467-023-35882-w.
9
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.塔奎单抗,一种用于多发性骨髓瘤的靶向 GPRC5D 的 T 细胞双特异性抗体。
N Engl J Med. 2022 Dec 15;387(24):2232-2244. doi: 10.1056/NEJMoa2204591. Epub 2022 Dec 10.
10
The emerging therapeutic landscape of relapsed/refractory multiple myeloma.复发/难治性多发性骨髓瘤的新兴治疗领域。
Ann Hematol. 2023 Jan;102(1):1-11. doi: 10.1007/s00277-022-05058-5. Epub 2022 Dec 3.